Berkshire requires a 25–50% discount to intrinsic value before buying.
Buffett Quality Checklist
✗ROE >15% consistently (≥7 of last 10 years)
✓Free cash flow positive (≥8 of last 10 years)
✓Conservative leverage — Debt/Equity below 1
✓Revenue growing at CAGR >5%
✓EPS growing at CAGR >5%
10-Year Financial History — SEC EDGAR 10-K Filings
Year▲
Revenue▲
Net Income▲
FCF▲
Owner Earnings▲
ROE▲
Net Margin▲
LT Debt▲
Cash▲
2016
$7.7B
$305.9M
$1.4B
$1.2B
3.2%
4.0%
$10.7B
$634.1M
2017
$7.8B
$1.8B
$1.4B
$2.7B
15.5%
23.2%
$8.9B
$524.4M
2018
$7.9B
-$379.2M
$1.6B
$498.6M
-3.4%
-4.8%
$8.4B
$542.8M
2019
$8.0B
$1.1B
$1.4B
$1.9B
9.1%
14.2%
$6.7B
$617.9M
2020
$6.1B
-$138.9M
$1.1B
$647.6M
-1.1%
-2.3%
$7.6B
$802.1M
2021
$6.8B
$401.6M
$1.4B
$1.2B
3.2%
5.9%
$1.0B
$378.1M
2022
$6.9B
$231.4M
—
$969.9M
1.9%
3.3%
$5.2B
$375.7M
2023
$7.4B
$1.0B
$1.3B
$1.7B
8.2%
13.8%
$4.9B
$415.8M
2024
$7.7B
$903.8M
$1.3B
$1.7B
7.2%
11.8%
$5.3B
$525.5M
2025
$8.2B
$705.1M
$1.5B
$1.6B
5.6%
8.6%
$6.9B
$591.9M
Warren & Charlie
Buffett / Munger — quality, moat & valuation
ZIMMER BIOMET HOLDINGS, INC. (ZBH) — Investment Memo
🐂 The Bull Case (Warren's voice)
The Demographic Tailwind: We aren't betting on innovation; we are betting on the inevitable decay of the human body. As the population ages, the demand for hips and knees is a mathematical certainty.
The Behavioral Moat: The "switching cost" here isn't a contract; it's muscle memory. A surgeon who has performed 1,000 replacements with ZBH tools views switching brands as a risk to their reputation and patient outcomes.
Cash Flow Reliability: While growth is stagnant, the business produces a consistent $1.5B in FCF. It is a "toll bridge" on the road to mobility for the elderly.
Attractive Entry: If the market prices this as a dying business rather than a stable utility, we can buy a perpetuity of cash flows at a significant discount to replacement cost.
Price Range: Genuinely attractive only when the yield on FCF provides a meaningful cushion against the lack of organic growth.
🐻 The Bear Case (Charlie inverts)
The Commodity Trap: There is nothing "magical" about a piece of titanium. If a competitor produces a joint that is 10% better or 20% cheaper, and the hospital administration (the payer) overrides the surgeon (the user), the moat evaporates overnight.
The Innovation Treadmill: Management is spending millions on "technology and data" just to stay in the same place. They are running a race where the finish line moves every time they take a step; spending capital just to prevent decline is not investing, it's maintenance.
The Regulatory Guillotine: A structural shift in Medicare reimbursement or a government-mandated price cap on joint replacements would permanently impair the ability to maintain margins.
Most Likely Failure: The Innovation Treadmill. Over the next 5–10 years, if robotic surgery standardizes the process, the "surgeon habit" moat disappears because the robot—not the human—dictates the tooling.
💰 Valuation & Margin of Safety
Intrinsic value estimate: $110.75 per share
25% margin of safety entry: $83.06(conservative)
50% margin of safety entry: $55.38(Buffett's ideal)
Current Status: Fairly valued to slightly overvalued based on the provided DCF. Given the 0.2% FCF CAGR, there is no "growth" premium to be paid. We are buying a statue, and the market is pricing it like a sculpture.
Verdict: PASS
The business is a stagnant utility masquerading as a med-tech leader. With FCF growth of 0.2%, we are paying for a "moat" that is merely a collection of old habits. We don't buy statues; we buy compounding machines.
Other Analyst Views· Lynch · Damodaran
Research Notes· Money Model · Moat · Financials · Management
Data sourced from SEC EDGAR XBRL filings (10-K only). For educational purposes — not investment advice.